In the event that the present inoculation is ineffective against the new strain, Pfizer has already begun developing a version of its Covid-19 vaccine that particularly targets the ‘Omicron’ variation, according to Pfizer CEO Albert Bourla.
According to Bourla, his company began testing the current vaccine against the ‘Omicron’ form on Friday, which was initially discovered in South Africa and revived worries of a global Covid-19 outbreak.
“I don’t think the result will be the vaccines don’t protect,” Bourla said.
But the testing could show that existing shots “protect less,” which means “that we need to create a new vaccine,” Bourla said.
“Friday we made our first DNA template, which is the first possible inflection of the development process of a new vaccine,” he said.
Bourla likened the situation to the scenario earlier this year when Pfizer and its German partner BioNTech developed a vaccine in 95 days when there were concerns the previous formula would not work against Delta, though that version ultimately was not used.
The current vaccine is “very effective” against Delta, the executive said, adding that the companies expect to be able to produce four billion vaccine doses in 2022.
On Monday, the World Health Organization warned the new Covid-19 ‘Omicron’ variant poses a “very high” risk globally.
Bourla said he was also “very confident” that Pfizer’s recently unveiled antiviral pill would work as a treatment for infections caused by the mutations, including ‘Omicron’.
Among newly-infected, high risk patients treated within three days of the onset of symptoms, Pfizer’s pill has been shown to cut hospitalization or death by nearly 90 percent.
